#1 Clinical Trials Search in Europe

Study of Venetoclax, Daratumumab, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

1 1 1

What is this study about?

This clinical trial is focused on studying a condition called Multiple Myeloma, which is a type of cancer that affects plasma cells in the bone marrow. The study is exploring the effectiveness of a combination of treatments for patients whose disease has returned or has not responded to previous treatments. The treatments being tested include Venetoclax (also known by its code name ABT-199), Daratumumab (marketed as Darzalex), Dexamethasone, and Bortezomib (marketed as Velcade). These medications are used in different combinations to see how well they work together in treating this condition.

The purpose of the study is to evaluate how these combinations of medications can help patients with relapsed or refractory multiple myeloma, particularly those with a specific genetic feature known as t(11;14) positive. The study will involve giving these medications to participants through different methods, such as intravenous (IV) infusion, subcutaneous injection, or oral tablets, depending on the medication. Some participants may receive a placebo as part of the study. The trial will monitor how the disease responds to these treatments over time, including how long it takes for the treatment to start working and how long the effects last.

Participants in the study will receive regular check-ups and monitoring to assess their response to the treatment and to ensure their safety. The study aims to gather information on the overall response rate, the time it takes for the disease to progress, and the overall survival of participants. This information will help researchers understand the potential benefits and risks of these treatment combinations for people with multiple myeloma.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and current health status.

Blood tests and other diagnostic procedures are performed to ensure the participant meets the study criteria.

2 treatment phase 1

Participants receive a combination of medications: venetoclax, daratumumab, and dexamethasone. This combination is referred to as VenDd.

Daratumumab is administered as an intravenous infusion. The frequency and dosage are determined by the study protocol.

Venetoclax is taken orally in the form of film-coated tablets. The dosage is adjusted based on individual response and tolerance.

Dexamethasone is administered as part of the treatment regimen to manage inflammation and other symptoms.

3 treatment phase 2

For some participants, the treatment includes an additional medication, bortezomib, along with venetoclax, daratumumab, and dexamethasone. This combination is referred to as VenDVd.

Bortezomib is administered either as an intravenous infusion or a subcutaneous injection, depending on the participant’s condition and response.

4 monitoring and evaluation

Throughout the study, regular monitoring is conducted to assess the participant’s response to the treatment.

This includes blood tests, imaging studies, and other evaluations to measure the effectiveness of the therapy and monitor for any side effects.

5 follow-up

After completing the treatment phases, participants undergo a follow-up period to evaluate long-term outcomes.

The follow-up includes periodic health assessments and monitoring of disease progression or remission.

Who Can Join the Study?

  • The participant must have a performance status of 2 or less on the Eastern Cooperative Oncology Group (ECOG) scale, which measures how well a person can perform daily activities.
  • The participant must have relapsed or refractory multiple myeloma, meaning the disease has returned or is not responding to treatment, with proof of worsening condition during or after the last treatment.
  • The participant must have a measurable disease confirmed by a central lab at the start of the study. This can be shown by one of the following:
    • Serum M-protein level of 1.0 g/dL or higher.
    • Urine M-protein level of 200 mg/24 hours or higher.
    • Serum free light chain (FLC) level of 10 mg/dL or higher, with an abnormal FLC ratio, for those without measurable disease by other tests.
  • The participant must have received previous treatment for multiple myeloma as specified in the study protocol.
  • Bone marrow samples must have been collected from the participant.
  • For certain parts of the study, the participant must be t(11;14) positive, which is a specific genetic marker, as determined by a special lab test called Fluorescent In Situ Hybridization (FISH).
  • The participant must have adequate blood, kidney, and liver function.

Who Cannot Join the Study?

  • Patients who have not been diagnosed with Multiple Myeloma cannot participate. Multiple Myeloma is a type of cancer that affects certain cells in the bone marrow.
  • Patients who have not received at least one previous treatment for Multiple Myeloma that included a proteasome inhibitor and an immunomodulatory agent cannot participate. A proteasome inhibitor is a drug that blocks the action of proteasomes, which are parts of cells that break down proteins. An immunomodulatory agent is a drug that helps regulate or normalize the immune system.
  • Patients who are considered refractory to proteasome inhibitors cannot participate. Refractory means that the disease does not respond to treatment.
  • Patients who have received more than three previous treatments for Multiple Myeloma cannot participate.
  • Patients who are not within the specified age range for the study cannot participate. The age range is typically defined by the study and may include adults and older adults.
  • Patients who are not able to provide informed consent or who are part of a vulnerable population that requires special protection cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Institut Gustave Roussy Villejuif France

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Poitiers Poitiers France
Odense University Hospital Odense Denmark
Sygehus Lillebaelt Vejle Sygehus Vejle Denmark
Medical Center – University Of Freiburg Freiburg Im Breisgau Germany
Centre Hospitalier Universitaire De Nantes Nantes France
Rigshospitalet Copenhagen Denmark
Csmctw Huenoqlvihx En Ugjxbsmarelun De Lrurrkw Limoges France
Cracht Hdhzdbrgvpn Rwbxiuyp Ucyzdrzirjlur Dq Thmmd Tours France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Denmark Denmark
Not recruiting
15.08.2018
France France
Not recruiting
15.08.2018
Germany Germany
Not recruiting
15.08.2018

Trial locations

Investigated drugs:

Venetoclax is a medication used in this trial to help treat multiple myeloma, a type of blood cancer. It works by targeting and blocking a specific protein that cancer cells need to survive, which may help to kill the cancer cells.

Daratumumab is an antibody therapy used in the trial. It attaches to a specific protein found on the surface of multiple myeloma cells. By doing this, it helps the immune system to identify and destroy these cancer cells.

Dexamethasone is a steroid medication included in the trial. It is used to reduce inflammation and suppress the immune system, which can help to manage symptoms and enhance the effectiveness of other cancer treatments.

Bortezomib is a medication that is sometimes added to the treatment combination in this trial. It works by interfering with the cancer cells’ ability to break down proteins, which can lead to the death of these cells.

Multiple Myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, cancerous plasma cells multiply and crowd out healthy blood cells, leading to bone damage, anemia, and increased risk of infections. As the disease progresses, it can cause bone pain, fractures, and kidney problems due to the accumulation of abnormal proteins produced by the cancerous cells. The disease often progresses in a relapsing and remitting pattern, where periods of active disease are followed by periods of remission. Over time, the disease can become resistant to treatment, making it more challenging to manage.

Trial ID:
2023-506110-43-00
Protocol code:
M15-654
NCT ID:
NCT03314181
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1
    Investigated drugs:
    Norway